Prevalence and Persistence of Maternal Dengue Neutralizing Antibodies in Infants From Central and Southern Thailand: A Retrospective Cohort Study. (May 2019)

• Record Type: Journal Article
• Authors: Guignard, Adrienne; Haguinet, François; Wéry, Stéphanie; Kerdpanich, Phirangkul
• Is Part Of: Asia-Pacific journal of public health. Volume 31:Number 4(2019)
• Page Start: 288
• Page End: 295
• Publication Date: 2019-05
• Subjects: dengue virus -- immunization -- infants -- maternal neutralizing antibodies -- persistence -- prevalence; Public health -- Pacific Area -- Periodicals; Public health -- Asia -- Periodicals; 362.1095
• DOI: 10.1177/1010539519853396
• Languages: English
• ISSNs: 1010-5395

Abstract

Understanding maternal dengue virus (DENV) neutralizing antibody kinetics in infants remains timely to develop a safe and effective childhood immunization. This retrospective study evaluated the prevalence and persistence of maternal antibody titers against DENV serotypes 1 to 4 in 139 Thai infants at 2, 6, and 7 months of age, using serum samples collected in a vaccination trial (http://clinicaltrials.gov ; NCT00197275). Neutralizing antibodies against all 4 DENV serotypes were detected in 87.8% and 22.9% of infants at 2 and 7 months, respectively. At 2 months, DENV-4 neutralizing antibody geometric mean titers were notably lower (80) compared with DENV-1 to DENV-3 (277-471). Our results corroborate previous findings that DENV-1 to DENV-4 maternal antibodies persist at 7 months despite titers decrease from 2 months onwards. As persisting maternal antibodies may inhibit immune responses in DENV-vaccinated infants, a comprehensive understanding of DENV antibody kinetics is required in the perspective of vaccine development for infants.